CAHQueued from the May 25, 2026 S&P 500 market-cap snapshot ranks 201-225; refreshed with public Cardinal Health FY2025/FY2026 operating data and June 2026 market-data references.

Cardinal Health

Cardinal Health distributes pharmaceuticals, specialty medicines, medical products, and related logistics services for pharmacies, hospitals, health systems, and other care settings.

CompaniesMarketCap Product analyses

Metadata

Where this company sits

Ticker: CAH
Rank snapshot: ≈ 215
Sector: Health Care
Industry: Health Care Distributors
Region: United States
Index: S&P 500 · Top 225 by market cap

Metrics

Scoring view

Every metric is paired with a short rationale. The numbers are deliberate, not divine.

Moat

7.0/10

National distribution scale, regulated logistics, supplier relationships, and embedded pharmacy and hospital workflows create a strong operating moat, but the business remains exposed to contract churn and low-margin wholesale economics.

Decentralizability

4.0/10

Physical pharmaceutical and medical-product distribution is hard to decentralize, but inventory visibility, replenishment coordination, facility-level logistics, and cooperative procurement can be opened or federated.

Profitability

6.0/10

Cardinal Health reported fiscal 2025 segment profit growth across major businesses and raised FY2026 non-GAAP EPS guidance, but the distribution model remains very high revenue and comparatively thin margin.

Price / Earnings

30.5x

StockAnalysis listed Cardinal Health's P/E ratio around 30.48 near the June 2026 refresh window; this is market-data dependent and should be refreshed before investment use.

Market cap

$45.7B

StockAnalysis reported Cardinal Health market capitalization of $45.71 billion as of June 1, 2026.

Freed-up capital potential

$6.5B

Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.

Narrative

Why the company matters

A short editorial overview plus the current thesis on moat strength and decentralization pressure.

Business Mix

Cardinal Health is primarily a health-care distribution company, with its Pharmaceutical and Specialty Solutions segment producing the overwhelming majority of revenue and its Global Medical Products and Distribution segment adding medical-surgical products, branded supplies, and distribution services.

The company also operates at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics inside its other businesses, giving it exposure to home-care distribution, radiopharmaceutical services, and health-care freight optimization.

Scale Position

The scale of Cardinal Health's purchasing, inventory, compliance, and delivery network makes it hard for smaller operators to replicate its national coverage, especially in controlled, time-sensitive, and regulated categories.

The same scale also creates concentration and coordination risk: customers and suppliers depend on a few large intermediaries, while a meaningful part of the business is exposed to contract renewals, low gross-margin distribution economics, and regulatory scrutiny.

Moat reading

Cardinal Health's moat comes from procurement scale, supplier relationships, dense distribution infrastructure, regulated operating know-how, and embedded relationships with pharmacies, hospitals, and health systems. Its Pharmaceutical and Specialty Solutions segment reported $204.6 billion of fiscal 2025 revenue and $2.3 billion of segment profit, which shows a business with very large throughput and meaningful operating leverage.

The moat is not absolute. Pharmaceutical distribution is competitive, customer contracts can move revenue materially, and the company describes branded pharmaceutical mix as dilutive to gross margin. The result is a strong logistical and compliance moat with moderate pricing power rather than a high-margin software-like monopoly.

Decentralization reading

Cardinal Health is difficult to decentralize at the national wholesale level because drug distribution requires supplier contracts, credit, controlled-substance compliance, cold-chain controls, recalls, serialization, lot tracking, and dependable delivery across thousands of care sites.

The more plausible decentralization pressure is at the coordination and visibility layer: open logistics systems, shared inventory networks, cooperative purchasing groups, and facility-level stock tools can reduce information asymmetry and help regional or public-health networks operate without fully depending on one closed distributor stack.

Products

Where the moat actually touches users

These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 3 structured disruption concepts across the current product set.

3 disruption concepts tracked0 documented exceptions

Pharmaceutical distribution

Health-care distribution

1 concept

Cardinal Health distributes branded, generic, specialty, and related pharmaceutical products to pharmacies, health systems, and other care providers.

Open analysis

Medical products distribution

Medical products and logistics

2 concepts

Cardinal Health distributes medical-surgical products and related supplies to health systems, hospitals, laboratories, and other care settings.

Open analysis

Technology waves

Strategic lenses

These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.

Microfactories and automated mini-home production

Small, software-defined manufacturing cells could make localized production less eccentric and more default.

• Products with heavy branding but generic bill-of-materials profiles look increasingly vulnerable.
• Logistics moats still matter, but their margin for arrogance should narrow.
• Open-source production recipes can pressure both price and product differentiation.

Paper trail